Brazil Medical Device Risk Classification I–IV under RDC No. 751/2022: Rules, SaMD and IVD Boundaries

1. Key takeaways

Brazil divides medical device risk into four classes: Class I (low risk), Class II (medium risk), Class III (high risk) and Class IV (highest risk). The statutory anchor is Article 5 of RDC n° 751/2022 (resolution of September 15, 2022, effective March 1, 2023), while the determination rules sit in Article 9 and the 22 rules of Annex I.

GRZAN’s judgment: risk classification is not an administrative label attached to the dossier — it is a master switch. It simultaneously decides three things: whether the pathway is notification (notificação) or registration (registro), whether a good manufacturing practice certificate (CBPF) is required, and whether an optimized review procedure is available.

2. Legal basis

• Classification, notification and registration of medical devices, and labeling and instruction-for-use requirements — RDC n° 751/2022, resolution of September 15, 2022, Articles 5, 8, 9 and Annex I, and Article 67
• Rules for software as a medical device — RDC n° 657/2022, effective July 1, 2022, scope provisions
• Rules for in vitro diagnostic medical devices — RDC n° 830/2023, published in DOU No. 234 of December 11, 2023, Article 71
• Optimized review procedure — IN n° 290/2024, issued April 4, 2024 and effective June 3, 2024, Article 2

3. Expert insights

Why does Brazil place the determination rules in Annex I rather than the main text? GRZAN reads it as a way of keeping the core provisions stable: Article 5 gives the outcome, the annex carries the technical detail, and updating an annex is faster than amending the main text. The 22 rules fall into four blocks — Rules 1–4 non-invasive devices, Rules 5–8 invasive devices, Rules 9–13 active devices, and Rules 14–22 special rules. Reading the blocks in order matters in practice: most products are decided by a single rule, but multi-technology devices — an instrument with software, or a combination of invasive and active components — are pulled from several blocks at once, which is exactly where Article 8 comes in.

Article 8 is the provision GRZAN cites most often, because it governs four boundary situations: components of combination products are classified separately; accessories are classified separately; software that controls or influences the use of a device is classified together with that device; and standalone software (SaMD, software as a medical device) is classified on its own. Where several rules apply at once, the strictest one governs. Together with RDC n° 657/2022, which governs software as a medical device and took effect July 1, 2022, this forms the software half of the Brazilian classification architecture.

One official divergence in the software rules deserves a separate flag. ANVISA’s officially hosted English translation lists the SaMD rule as Rule 11 (decision-support software → Class II; where death or irreversible deterioration of health may occur → Class IV; where serious deterioration or surgical intervention is required → Class III; monitoring of physiological processes → Class II, but where vital physiological parameters are monitored and variation in those parameters may result in immediate danger to the patient → Class III; other SaMD → Class I), while the device webpage on the ANVISA site writes Rule 12. GRZAN follows the ordering of the official English translation and marks the divergence openly: when citing, check the rule number together with the article table.

Article 5, §2 supplies the fallback route: when classification is in doubt, ANVISA decides. This clause is often underestimated. Its existence shows that Brazil treats classification as a matter subject to regulatory confirmation, not a unilateral self-declaration by the company. Classification conclusions in international registration documents therefore cannot be copied into Brazilian filings, and a team that submits a foreign class conclusion without independent verification should expect a deficiency question on exactly that point.

The first pitfall companies hit is transplanting the classes of the US FDA or China’s NMPA into Brazil. The rules of different jurisdictions are independent, and the same product may fall into a neighboring class in Brazil. The second pitfall is group filing: when families, systems and kits are filed together, a single member crossing into another class prevents the whole group from using the lighter low-risk pathway. The third pitfall is IVD — in vitro diagnostic devices have their own rule system under RDC n° 830/2023; separate them from the device portfolio first, then classify, and never reverse the order. Every one of these pitfalls ends the same way: the class conclusion was borrowed instead of derived, and the error surfaces only after submission, when re-planning is most expensive.

For products at the boundary between neighboring classes, GRZAN’s rule of thumb is to prepare documentation at the higher risk class and converge downward as evidence firms up. The cost of trimming down early is far lower than the cost of under-preparing a set of files — and a downgrade after filing is a far smoother conversation with ANVISA than an upgrade discovered mid-review.

4. Practical recommendations

• Build a three-tier classification worksheet — applicable rule, class conclusion, supporting evidence — so every conclusion traces to a specific rule.
• When citing the SaMD rule, record both Rule 11 and the Rule 12 divergence on the official webpage to prevent later disputes.
• Before grouping families, systems and kits, check every member for class-crossing so a single product does not raise the obligations of the whole group.
• For higher-risk classes, first check whether acceleration applies: Article 2 of IN n° 290/2024 confines the optimized review to first marketing authorization applications of Class III and Class IV devices.
• IVDs follow RDC n° 830/2023 alone and are not classified under Article 5 of RDC n° 751/2022.
• For borderline products with genuine doubt, use the ANVISA determination route under Article 5, §2 and keep records of the exchanges.
• Once a class conclusion changes, recalculate CBPF, language requirements and UDI timelines together — do not only amend the filing form.

5. Verification checklist

• □ The four-class statutory wording has been checked against Article 5 of RDC n° 751/2022
• □ The applicable rule numbers have been checked in Article 9 and Annex I and documented
• □ The product has been confirmed to fall outside the IVD scope of RDC n° 830/2023
• □ SaMD has been assessed separately under Rule 11, with RDC n° 657/2022 cross-checked
• □ Family and kit groupings have undergone member-by-member class-crossing checks

Regulatory information verified as of October 29, 2026.

GRZAN Regulatory Team

GRZAN provides registration and compliance support for medical device and IVD manufacturers entering the Brazilian market, covering classification analysis, ANVISA pathway strategy, dossier preparation, CBPF coordination and post-market compliance. For assistance with Brazilian regulatory requirements, contact info@grzanglobal.com.